TMCnet News
Jounce Therapeutics Added to NASDAQ Biotechnology IndexCAMBRIDGE, Mass., Dec. 14, 2017 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers for patient enrichment, today announced that it has been selected for addition to the NASDAQ Biotechnology Index®. The addition will take effect prior to the open of the U.S. markets on Monday, December 18, 2017. The NASDAQ Biotechnology Index (NBI) contains securities of NASDAQ-listed companies classified according to the Industry Classification Benchmark as either Biotechnology or Pharmaceuticals. Companies in the NBI must meet eligibility requirements, including minimum market capitalization and average daily trading volume, among other criteria. The NASDAQ Biotechnology Index is re-ranked annually and forms the basis for a number of Exchange Traded Funds (ETFs), including the iShares NASDAQ Biotechnology ETF. For more information about theNASDAQ Biotechnology Index visit https://indexes.nasdaqomx.com/Index/Overview/NBI. About Jounce Therapeutics Investor Contact: Media Contact: |